Non-Small-Cell Lung Cancer | Unmet Need | US/EU5 | 2020

Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint inhibitor-based therapy such as Keytruda (Merck & Co.), Opdivo plus Yervoy (Bristol Myers Squibb), Tecentriq (Roche), and Libtayo (Sanofi / Regeneron). Targeted therapies such as the EGFR inhibitor Gilotrif / Giotrif (Boehringer Ingelheim) are available for some patients in subsequent lines, but not all patients respond to treatment. The lack of biomarker-driven therapies leaves patients with metastatic squamous NSCLC with fewer treatment options compared with other NSCLC patient populations. Thus, a strong need remains for more-effective treatments for this patient population.

QUESTIONS ANSWERED

What are the drivers of and constraints on the treatment of metastatic squamous NSCLC?
How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for metastatic squamous NSCLC?
What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
· What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for metastatic squamous NSCLC?

CONTENT HIGHLIGHTS

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2021.

Key companies: Merck & Co., Bristol Myers Squibb, Roche / Genentech, Sanofi / Regeneron, Boehringer Ingelheim.

Key drugs: Keytruda, Opdivo + Yervoy, Tecentriq, Libtayo, Gilotrif / Giotrif, Abraxane.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator

Contact sales account_box

Report

Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)

Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…

north_east

Report

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…

north_east

Report

Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

north_east

Report

Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight

Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…

north_east

Report

Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)

The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…

north_east

Product logins

Non-Small-Cell Lung Cancer | Unmet Need | US/EU5 | 2020

Related Market Assessment Reports

Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)

Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)

Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer

Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight

Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)

Follow us

Contact us